deltatrials
Completed PHASE1/PHASE2 NCT00002577

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

A PHASE I/II DOSE ESCALATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY POST INDUCTION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE, NON-SMALL CELL LUNG CANCER

Sponsor: National Cancer Institute (NCI)

Conditions Lung Cancer
Interventions radiation therapy
Updated 6 times since 2017 Last updated: Nov 18, 2013 Started: Jul 31, 1995 Primary completion: Jan 31, 2003

This PHASE1/PHASE2 trial investigates Lung Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1995 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jul 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Radiation Therapy Oncology Group
Data source: Radiation Therapy Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albany, United States, Albuquerque, United States, Allentown, United States, Amarillo, United States, Anchorage, United States, Anderson, United States, Ann Arbor, United States, Annapolis, United States, Arlington Heights, United States and 178 more location s